Composition capable of enhancing organism immunity and application of composition to resisting adult T-cell leukemia or nasopharyngeal carcinoma

Abstract

The invention provides a composition capable of enhancing organism immunity and an application of the composition to resisting adult T-cell leukemia or nasopharyngeal carcinoma. The composition contains a dendritic cell vaccine and a novel immunity checkpoint inhibitor NKG2A antagonist, and is used for treating the adult T-cell leukemia and the nasopharyngeal carcinoma. The source of dendritic cells in the composition is firstly dendritic cells extracted from patients or animals, when the extracted dendritic cells are mature after being cultured in vitro and induction, specific cancer antigensare loaded to the dendritic cells which are extracted from the patients or the animals, corresponding antigens are formed on the surfaces of the dendritic cells, then the dendritic cells having the corresponding antigens on the surfaces and an NKG2A antagonist are transported back to patient bodies together to stimulate natural immunity and induce natural killer cells and T lymphocyte to producean acquired immunity reaction, the quantity of in vivo viruses is reduced, and cytotoxic T cells are activated to kill and destroy cancer cells to treat the adult T-cell leukemia and the nasopharyngeal carcinoma.

Description

technical field [0001] The invention relates to the technical field of biological immunity, in particular to a composition for improving body immunity and its application in anti-adult T-cell leukemia or nasopharyngeal carcinoma. Background technique [0002] Dendritic cells (DC) were discovered in 1973 by Canadian scientist Ralph M. Steinman, who won the Nobel Prize in Medicine and Physiology in 2011, and are named for their many dendritic or pseudopodia-like protrusions when they mature. DCs are the professional antigen presenting cells (Antigenpresenting cells, APCs) with the strongest function in the body known so far, which can efficiently uptake, process and present antigens, and are the only ones found so far that can activate unsensitized naive T cells. APC; and immature DC has a strong ability to migrate and present antigens, and mature DC can effectively activate naive T cells, and is at the center of initiating, regulating, and maintaining immune responses. Its n...

AI Technical Summary

Problems solved by technology

The immune response elicited by most dendritic cell vaccines fails to recognize virus-exposed cancer cells because the surface of the virus-infected and cancerous cells expresses immune checkpoint molecules under the influence of the virus's genome that prevent it from being recognized by the immune system. Cells cannot effectively kill tumors, and the therapeutic effect is limited

[0015] 2. At present, the target antigens of most dendritic cell vaccines are expressed not only on cancer cells but also on a few normal cells. The immune system has a certain chance to attack normal cells and cause other adverse side effects

[0016] 3. The existing dendritic cell vaccines require dendritic cells to present tumor surface antigens or exogenous viral antigens to the immune system, and gradually initiate immunity, which is slow to take effect, and the treatment process is slower than other immunotherapies such as CAR-T. for long

[0017] 4. In the body, because many tumor cells can secrete a variety of cytokines that inhibit the maturation of dendritic cells, the number of dendritic cells present in the tumor site is relatively small, and the down-regulation of the expression of MHC molecules on the surface of dendritic cells affects its function , the immune response induced by dendritic cells against viral infectious tumors cannot play a very significant therapeutic effect in the host body, and most of them can only achieve partial remission

Images